LB Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	320.68	250.17	22.98	14.98	21.4
Short-Term Investments	44.96	45.04	5.02	28.31	-
Cash & Short-Term Investments	365.64	295.21	28	43.29	21.4
Cash Growth	1205.89%	954.37%	-35.32%	102.26%	-
Other Current Assets	23.44	13.22	0.88	2.34	0.09
Total Current Assets	389.07	308.43	28.88	45.63	21.49
Net Property, Plant & Equipment	3.63	3.73	4.16	0.02	0
Other Long-Term Assets	0.78	0.77	0.5	-	-
Total Assets	393.48	312.93	33.53	45.66	21.49
Accounts Payable	7.12	2.13	2.32	1.39	0.16
Accrued Expenses	3.06	4.59	5.3	1.22	0.31
Current Portion of Leases	0.73	0.73	0.49	-	-
Total Current Liabilities	10.91	7.44	8.11	2.61	0.47
Long-Term Debt	-	-	-	-	24.15
Long-Term Leases	2.74	2.84	3.22	-	-
Other Long-Term Liabilities	1.14	1.34	2.5	1.56	18.49
Total Long-Term Liabilities	3.88	4.18	5.72	1.56	42.64
Total Liabilities	14.79	11.62	13.83	4.16	43.11
Common Stock	0	0	0	0	0
Additional Paid-in Capital	527.06	430.67	9.66	6.47	6.13
Accumulated Other Comprehensive Income	0.21	0.17	0.11	0.27	-
Retained Earnings	-148.58	-129.53	-104.32	-41.22	-34.95
Total Common Shareholders' Equity	378.69	301.31	-94.55	-34.47	-28.81
Minority Interest	-	-	114.26	75.97	7.19
Shareholders' Equity	378.69	301.31	19.71	41.49	-21.62
Total Liabilities & Equity	393.48	312.93	33.53	45.66	21.49
Total Debt	3.47	3.57	3.7	0	24.15
Net Cash (Debt)	362.17	291.64	24.3	43.29	-2.74
Net Cash Growth	24.18%	1100.38%	-43.88%	-	-
Net Cash Per Share	12.63	36.25	67.82	150.75	-11.88
Book Value	378.69	301.31	-94.55	-34.47	-28.81
Book Value Per Share	13.21	37.45	-263.95	-120.05	-124.68
Tangible Book Value	378.69	301.31	-94.55	-34.47	-28.81
Tangible Book Value Per Share	13.21	37.45	-263.95	-120.05	-124.68

SEC Filings: 10-K · 10-Q